DexCom Ownership
| DXCM Stock | USD 85.12 1.09 1.30% |
Shares in Circulation | First Issued 2005-03-31 | Previous Quarter 406.7 M | Current Value 407.5 M | Avarage Shares Outstanding 287.6 M | Quarterly Volatility 114.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. DexCom Stock Ownership Analysis
About 97.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 1.3. DexCom Inc had not issued any dividends in recent years. The entity had 4:1 split on the 13th of June 2022. DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Dexcom operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 6300 people. To learn more about DexCom Inc call Kevin Sayer at 858 200 0200 or check out https://www.dexcom.com/global.Besides selling stocks to institutional investors, DexCom also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different DexCom's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align DexCom's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
DexCom Quarterly Liabilities And Stockholders Equity |
|
DexCom Insider Trades History
Less than 1% of DexCom Inc are currently held by insiders. Unlike DexCom's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against DexCom's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of DexCom's insider trades
DexCom Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as DexCom is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading DexCom Inc backward and forwards among themselves. DexCom's institutional investor refers to the entity that pools money to purchase DexCom's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 6.6 M | Amundi | 2025-03-31 | 5.5 M | Amvescap Plc. | 2025-03-31 | 5.3 M | Norges Bank | 2024-12-31 | 5 M | Bank Of New York Mellon Corp | 2025-03-31 | 4.5 M | Jpmorgan Chase & Co | 2025-03-31 | 4.1 M | American Century Companies Inc | 2025-03-31 | 4.1 M | Northern Trust Corp | 2025-03-31 | 3.9 M | Bank Of America Corp | 2025-03-31 | 3.5 M | Vanguard Group Inc | 2025-03-31 | 47.5 M | Blackrock Inc | 2025-03-31 | 39.2 M |
DexCom Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DexCom insiders, such as employees or executives, is commonly permitted as long as it does not rely on DexCom's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases DexCom insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
DexCom's latest congressional trading
Congressional trading in companies like DexCom Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in DexCom by those in governmental positions are based on the same information available to the general public.
| 2025-07-09 | Representative Michael McCaul | Acquired $15K to $50K | Verify | ||
| 2025-06-10 | Representative Rob Bresnahan | Acquired Under $15K | Verify | ||
| 2025-05-15 | Representative Michael McCaul | Acquired $50K to $100K | Verify | ||
| 2025-05-09 | Representative Jefferson Shreve | Acquired $15K to $50K | Verify | ||
| 2025-04-29 | Representative Rob Bresnahan | Acquired Under $15K | Verify | ||
| 2025-04-18 | Representative Michael McCaul | Acquired $15K to $50K | Verify | ||
| 2025-03-28 | Representative Rob Bresnahan | Acquired Under $15K | Verify | ||
| 2020-04-16 | Senator Tina Smith | Acquired $250K to $500K | Verify | ||
| 2020-04-15 | Senator Tina Smith | Acquired $250K to $500K | Verify | ||
| 2018-07-15 | Representative Bradley S Schneider | Acquired $100K to $250K | Verify |
DexCom Outstanding Bonds
DexCom issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. DexCom Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most DexCom bonds can be classified according to their maturity, which is the date when DexCom Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
DexCom Corporate Filings
F4 | 17th of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 7th of July 2025 Other Reports | ViewVerify | |
| 29th of May 2025 Other Reports | ViewVerify | |
8K | 13th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.26) | Earnings Share 1.33 | Revenue Per Share | Quarterly Revenue Growth 0.125 | Return On Assets |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.